Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study

International Journal of Retina and Vitreous

Vishali Gupta¹  Vinu Jose²  Ronak Patel³  Sandeep Saxena⁴  Rahul Mayor⁵  Raju Sampangi⁶  Neha Goel⁷  Sandhya Dharwadkar⁸  Soumyava Basu⁹  Vivek Dave⁹  Shrinivas Joshi^1,10  Shashikant Sharma^1,11  Alok Chaturvedi^1,11  Naresh Kumar Yadav^1,12  Sribhargava Natesh^1,13  Vimal Parmar^1,14  Hemanth Murthy^1,15  Dhanashree Ratra^1,16  Aniruddha Maiti^1,17 

[1] Advanced Eye Centre, Postgraduate Institute of Medical Education and Research;Clinical Development & Medical Affairs, Intas Pharmaceuticals Ltd. (Biopharma);Department of Biostatistics and Programming, Lambda Therapeutic Research Ltd.;Department of Ophthalmology, King George’s Medical University;Dr. Shroff’s Charity Eye Hospital;Gurushree Hi-Tech Multi Speciality Hospital;ICARE Eye Hospital & Post Graduate Institute;K.R. Hospital, Mysore Medical College & Research Institute;L V Prasad Eye Institute;M M Joshi Eye Institute;Medical Affairs, Intas Pharmaceuticals Ltd;Narayana Nethralaya;Nethra Eye Hospital;PBMA’s H. V. Desai Eye Hospital;Retina Institute of Karnataka;Sankara Nethralaya;Susrut Eye Foundation & Research Centre;

关键词: Razumab;    Biosimilar ranibizumab;    Neovascular;    Wet age-related macular degeneration;    AMD;    Safety;   

DOI  :  10.1186/s40942-021-00293-w

来源: DOAJ

【 摘 要 】

Abstract Background Razumab™ (world’s first biosimilar ranibizumab) is approved for several macular disorders including wet age-related macular degeneration (AMD). We evaluated the safety and efficacy of biosimilar ranibizumab in wet AMD. Methods This prospective, multicentre, rAnibizumab bioSimilar Safety Efficacy postmarkeTing (ASSET) study enrolled patients aged ≥ 50 years with wet AMD having best-corrected visual acuity (BCVA) between 20/40 and 20/320. The patients received intravitreal biosimilar ranibizumab 0.5 mg every 4 weeks for 24 weeks. Safety endpoints included the incidence of adverse events (AEs), serious AEs (SAEs), and immunoreactivity after 6 months. The efficacy endpoints were the proportion of patients who lose fewer than 15 letters, increase in BCVA, change in central retinal thickness (CRT), and change in Visual Function Questionnaire-25 (VFQ-25) score, from baseline to 24 weeks. Results Of the 126 enrolled patients, majority (95.24%) of the patients received all 6 doses of biosimilar ranibizumab (total 3 mg). Nineteen AEs were reported (n = 16; 12.7%); majority (78.9%) were mild. There were no serious AEs reported, except one AE of death which was unrelated to the study drug. None of the patients discontinued the study due to an AE. The most common ocular AE was increase in intraocular pressure (4 events) and non-ocular AE was pyrexia (5 events). A total of 7.9% (10/126) patients prior to dosing and 7.1% (9/126) patients post-treatment were positive for anti-ranibizumab antibodies. No AEs suggestive of immunogenicity were noted. At 24-weeks, 97.60% patients in the intent-to-treat (ITT) population (N = 125) and 97.41% patients in the per-protocol (PP) population (N = 116) lost < 15 letters from baseline visual acuity. In the ITT and PP populations, 31.20% and 32.76% patients, respectively, showed improved visual acuity by ≥ 15 letters. Significant improvements in BCVA (mean difference: 8.8, 9.2, p < 0.001 for ITT, PP) and VFQ-25 (8.5, 9.2, p < 0.001 for ITT, PP) were seen; CRT reduced significantly (125 µm, 119.3 µm, p < 0.001 for ITT, PP). Conclusion Razumab™ (world’s first biosimilar ranibizumab) was well-tolerated without new safety concerns and significantly improved visual acuity in wet AMD patients. Trial registration CTRI/2016/03/006739. Registered 18 March 2016—Prospectively registered, http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=13141&EncHid=&userName=2016/03/006739

【 授权许可】

Unknown